Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...
Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...
Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...
Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.
Hosted on MSN10d
Clea Shearer Continues To Share Her Breast Cancer Journey: “I Was So Desperate for Information”One of those is taking Verzenio, a daily pill “to treat adults with HR+ [and] HER2,” its maker, Eli Lilly & Company ... how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback